Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study

Journal of the National Cancer Institute

Volumn 106, Issue 2, 2014, Pages

  Shapiro, Samuel ^a   Devilliers, Tobie J ^b   Pines, Amos ^c   Sturdee, David W ^d   Archer, David F ^e   Baber, Rod J ^f   Panay, Nick ^g   Farmer, Richard D T ^a   Stevenson, John C ^h   Mueck, Alfred O ⁱ   Burger, Henry G ^j   Gompel, Anne ^k  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c TEL AVIV UNIVERSITY   (Israel)

^d SOLIHULL HOSPITAL   (United Kingdom)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF SYDNEY   (Australia)

^g QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^k UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; FOLLOW UP; HUMAN; LETTER; MAMMOGRAPHY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; WOMEN'S HEALTH;

EID: 84893835823     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt372     Document Type: Letter

References (7)

1. Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst. 2013;105(8):526-535.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Newcomb PA, Egan KM, Trentham-Dietz LT, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:864-871.
4. Shapiro S, Farmer R D T, Mueck A, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 2. The Women's Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care. 2011;37:165-172.
5. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. New Engl J Med. 2009;360:573-584.
6. Hersh AL, Stefanick ML, Stafford RL. National use of menopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
7. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103-111.